STANDARD BIOTOOLS INC SEC Filings

Standard BioTools Inc. filed a Form 8-K to furnish a press release containing certain preliminary, unaudited financial results for the three months and fiscal year ended December 31, 2025. These figures are based on current expectations and may be adjusted after completion of the company’s year-end audit, financial closing procedures, and internal reviews.

The press release is included as Exhibit 99.1. The company notes that this information, including the exhibit, is being furnished rather than filed under the Securities Exchange Act, which limits its use for certain legal purposes.

Standard BioTools Inc. received a Schedule 13G filing showing that investment entities affiliated with MAK Capital have become significant shareholders. MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman together report beneficial ownership of 19,967,565 shares of Standard BioTools common stock, representing 5.19% of the outstanding shares. The percentage is based on 384,565,414 shares outstanding as of November 2, 2025, and MAK’s position as of January 7, 2026. The reporting parties state that the securities were not acquired and are not held for the purpose of changing or influencing control of the company, and they hold shared voting and dispositive power over all reported shares.

STANDARD BIOTOOLS INC. (LAB)11/24/2025, they bought 150,000 shares of common stock at a weighted average price of $1.4325 per share. On 11/25/2025, they bought an additional 7,550,000 shares at a weighted average price of $1.3031 per share.

Following these transactions, one indirect holding line shows 71,750,000 shares beneficially owned, with ownership attributed to Casdin Partners Master Fund, L.P. and related entities. The filing also reports 2,901,062 shares held directly by Eli Casdin and additional indirect holdings of 13,939,637 and 2,744,219 shares through other Casdin-managed funds, reflecting a sizable continuing stake in LAB.

Standard Biotools Inc. (LAB) reported an insider equity transaction by its President & CEO and director, Michael Egholm. On 11/20/2025, the company withheld 63,529 shares of common stock at $1.28 per share to cover tax withholding obligations that arose when previously granted restricted stock units vested. After this tax withholding transaction, Egholm beneficially owned 5,617,837 shares of Standard Biotools common stock directly.

Standard Biotools Inc. (LAB) reported an insider equity transaction by its Chief Financial Officer on 11/20/2025. The Form 4 shows that 12,739 shares of common stock were withheld at a price of $1.28 per share to cover tax obligations arising from the vesting of restricted stock units previously granted on May 20, 2024 and March 21, 2025. After this tax withholding transaction, the reporting person beneficially owns 2,415,086 shares of Standard Biotools common stock, held directly.

Standard BioTools Inc. (LAB) executive Sean Mackay, SVP & Chief Business Officer, reported a routine equity transaction on Form 4. On 11/20/2025, 19,661 shares of common stock were withheld at a price of $1.28 per share, indicated by transaction code "F," to cover tax obligations arising from the vesting of previously granted restricted stock units. After this tax withholding, Mackay beneficially owns 779,835 shares of Standard BioTools common stock directly.

Standard BioTools Inc. (LAB) large shareholder and director-affiliated entities managed by Eli Casdin reported open-market purchases of common stock. On 11/18/2025, they bought 275,000 shares at a weighted average price of $1.2342, followed by 350,000 shares at $1.2826 on 11/19/2025 and 450,000 shares at $1.3028 on 11/20/2025.

After these transactions, one indirect holding line shows 64,050,000 shares of LAB common stock, with other lines reporting 2,901,062 shares directly and additional indirect positions of 13,939,637 and 2,744,219 shares. The filing explains that various Casdin funds hold these positions and that Eli Casdin and related entities may be deemed to beneficially own the securities through their advisory and general partner roles, while each reports ownership only to the extent of its economic interest.

Standard BioTools Inc. (LAB) reported insider open-market purchases of its common stock by Casdin-affiliated investment entities that are directors and 10% owners. On 11/13/2025, they bought 450,000 shares at a weighted average price of $1.2031 per share. On 11/14/2025, they bought another 250,000 shares at a weighted average price of $1.2392, and on 11/17/2025, they bought 225,000 shares at a weighted average price of $1.2248.

Following these transactions, one indirect position is shown as 62,975,000 shares, with additional direct and indirect holdings of 2,901,062, 13,939,637, and 2,744,219 shares reported for various Casdin-managed funds and Eli Casdin. The filing notes that prices are weighted averages over multiple trades within stated ranges and that the securities of several funds may be deemed beneficially owned by Casdin Capital entities and Eli Casdin.

Standard BioTools (LAB) reported insider open‑market purchases by entities affiliated with Eli Casdin. The filing lists four buys totaling 1,175,000 shares on 11/07 (225,000 at a weighted average $1.1234), 11/10 (275,000 at $1.1706), 11/11 (300,000 at $1.196), and 11/12/2025 (375,000 at $1.1889).

Following these transactions, the Master Fund’s indirectly beneficially owned balance is stated as 62,050,000 shares. Additional positions reported include 2,901,062 shares held directly by Eli Casdin, 13,939,637 shares indirectly by Casdin Private Growth Equity Fund II, L.P., and 2,744,219 shares indirectly by Casdin Private Growth Equity Fund, L.P. The form is filed by more than one reporting person and marks the reporting persons as a director and 10% owner.